PK and PD of Sequential Multiple Ascending, Repeat Doses of Oral CXA-10 in Healthy Obese Male Subjects

NCT ID: NCT02460146

Last Updated: 2016-05-03

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 43 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-04-30
• Study Completion Date: 2015-10-31

Brief Summary

The main purpose of this trial is to demonstrate the safety, tolerability and pharmacokinetics (PK) of CXA-10 and its metabolite(s) administered as multiple ascending oral doses over 14 days to healthy obese male volunteers.

Detailed Description

Complexa has developed an oral formulation of CXA-10. The main purpose of this trial is to demonstrate the safety, tolerability and pharmacokinetics (PK) of CXA-10 and its metabolite(s) administered as multiple ascending oral doses over 14 days to healthy obese male volunteers. The pharmacodynamic (PD) effects of CXA-10 on serum biomarkers, some of which are elevated in the obese population, will also be investigated.

Conditions

Acute Kidney Injury

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

CXA-10

CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitrated oleic acid

Group Type: ACTIVE_COMPARATOR

CXA-10

Intervention Type: DRUG

CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitrated oleic acid

CXA-10 placebo

The placebo contains olive oil with BHT (0.08% to 0.10%).

Group Type: PLACEBO_COMPARATOR

CXA-10 placebo

Intervention Type: OTHER

The placebo contains olive oil with BHT (0.08% to 0.10%).

Interventions

CXA-10

CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitrated oleic acid

Intervention Type: DRUG

CXA-10 placebo

The placebo contains olive oil with BHT (0.08% to 0.10%).

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Body mass index (BMI) >27 and ≤40 kg/m2
• In good general health as determined by a thorough medical history and physical examination, ECG, vital signs, and clinical laboratory evaluation
• Results of clinical laboratory tests must be without clinically significant abnormalities for this population and may exceed the limits of the reference ranges, including hematology, clinical chemistry and urinalysis except as noted below
• Hemoglobin A1c (HbA1c) <7%
• Average blood pressure <160/100 mmHg at screening
• QTcF interval (Fredericia's correction factor) must be ≤430 msec at screening and pre-dose

Exclusion Criteria

• Any clinically relevant abnormality for this population identified on the screening history, physical or laboratory examinations, or any other medical condition or circumstance making the volunteer unsuitable for participation in the study
• Any clinical history of cardiovascular events, arrhythmias, fainting, palpitations, personal or family history of congenital prolonged QT syndromes or sudden unexpected death due to a cardiac reason
• History of any primary malignancy, including a history of melanoma or suspicious undiagnosed skin lesions, with the exception of basal cell or squamous cell carcinomas of the skin or cervical carcinoma in situ or other malignancies curatively treated and with no evidence of disease for at least 5 years
• History of regular alcohol consumption exceeding 21 units/week (one unit = 125 mL of wine or 284 mL of beer or a single 25 mL measure of spirits) within 6 months of screening
• Treatment with any prescription or non-prescription drugs (including vitamins, herbal and dietary supplements) within 7 days or 5 half-lives, whichever is longer, prior to dosing and until collection of the final PK sample. Use of any drug including aspirin or non-steroidal anti-inflammatory drugs (NSAIDs) must be avoided within 7 days prior to the first dose and during this study as it may interfere with the pharmacology of CXA-10. Use of high energy supplements or drinks (especially, those containing caffeine, protein supplements, and weight loss drugs)
• History of smoking, including e-cigarettes, or use of nicotine-containing products within 1 month of screening
• Resting heart rate ≥100 BPM after 5 minutes rest (as above) at the screening visit
• Subjects with any other clinically relevant ECG parameter abnormality (e.g., PR interval, QRS deviation) or any clinically significant ECG abnormality will be excluded from the study
• Any clinically significant murmurs evident on auscultation of the heart (including evidence of mitral valve prolapse)

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: Yes

Sponsors

Complexa, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Thomas Blok, MD

Role: PRINCIPAL_INVESTIGATOR

Jasper Clinic, Michigan

Locations

Jasper Clinical Research & Development, Inc.

Kalamazoo, Michigan, United States

Countries

United States

Other Identifiers

CXA-10-202

Identifier Type: -

Identifier Source: org_study_id